Abstract
We report a 14-year-old boy who developed acral erythema due to the chemotherapy for the conditioning of bone marrow transplantation (BMT). He was admitted to our hospital with the complaint of pancytopenia and diagnosed to have RAEB-T. When CR was achieved with low-dose Ara-C plus G-CSF therapy, allogeneic BMT was planned from his one-locus mismatched sister. Soon after the completion of conditioning regimen, sharply demarcated erythema became evident on the palms. For the treatment of severe pain, morphine was administered. The erythema gradually became dusky and resolved with marked desquamation over 10 days without any complication. Ara-C was suspected for the causative agent in our case. Acral erythema is known to be a complication in the patients treated with high-dose chemotherapy. It should be careful for its differentiation from GVHD in the recipients of BMT.
